Skip to main content
COO
NASDAQ Industrial Applications And Services

Cooper Companies Reports Q2 Net Loss Driven by $271.6M Litigation Charge; Extends $950M Term Loan

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$66.9
Mkt Cap
$13.139B
52W Low
$58.89
52W High
$89.83
52W Position info
14% above low
Off High info
26% below high
Rel. Volume info
3.6× avg
Market data snapshot near publication time

COO is trading near its 52-week low of $58.89 (14% above the low) on elevated volume (3.6× avg).

Summary

Cooper Companies reported a Q2 net loss of $77.9 million and an operating loss of $31.0 million, primarily due to a $271.6 million litigation accrual in its CooperSurgical segment, despite a 7.9% increase in net sales. The company also extended $950 million in term loan maturities.


Key Events · Earnings and Guidance · COO

  • Q2 Net Loss Reported

    The company reported a net loss of $77.9 million for the three months ended April 30, 2026, a significant decline from a net income of $87.7 million in the prior-year period. Diluted EPS was $(0.40) compared to $0.44 previously.

  • Major Litigation Accrual

    A net litigation expense of $271.6 million was recorded in the CooperSurgical segment, consisting of a $324.1 million accrued liability partially offset by $52.5 million in insurance recoveries. This charge was the primary driver of the Q2 operating and net losses.

  • Revenue Growth Continues

    Net sales increased by 7.9% to $1,081.5 million for Q2 2026, up from $1,002.3 million in Q2 2025. CooperVision net sales grew 8% and CooperSurgical net sales grew 8%.

  • Term Loan Maturity Extended

    $950.0 million of term loans under the 2021 Credit Agreement had their maturity date extended to February 3, 2031, improving the company's long-term debt profile.


Analysis · COO · Industrial Applications And Services

Cooper Companies reported a significant net loss and operating loss for Q2 2026, primarily due to a $271.6 million litigation expense related to its CooperSurgical segment. This charge overshadowed solid revenue growth in both CooperVision and CooperSurgical segments. While the company successfully extended $950 million of term loan maturities, the substantial litigation accrual represents a material financial hit that impacted profitability and working capital.

At the time of this filing, COO was trading at $66.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $13.1B. The 52-week trading range was $58.89 to $89.83. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

COO - Latest Insights

COO
Jun 05, 2026, 4:51 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $66.90
Real-time Price: $71.59 info
Change: +$4.69 (+7%) info
Market Cap: $13.962B info
COO
Jun 04, 2026, 4:27 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $63.30
Real-time Price: $71.59 info
Change: +$8.29 (+13%) info
Market Cap: $13.962B info
COO
Jun 04, 2026, 4:16 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $62.21
Real-time Price: $71.59 info
Change: +$9.38 (+15%) info
Market Cap: $13.962B info
COO
May 04, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $61.52
Real-time Price: $71.59 info
Change: +$10.07 (+16%) info
Market Cap: $13.962B info
COO
Mar 06, 2026, 4:12 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $76.73
Real-time Price: $71.59 info
Change: -$5.14 (-7%) info
Market Cap: $13.962B info